Oncotelic's 20nm Nanoparticle Technology Advances Cancer Treatment with Sapu003 Clinical Trial

Oncotelic Therapeutics Inc. has received Australian HREC approval to begin Phase 1 clinical trials for Sapu003, marking a significant advancement in nanomedicine cancer treatment. The company's proprietary Deciparticle(TM) platform utilizes precisely engineered 20nm nanoparticles to deliver Everolimus (Afinitor(R)) intravenously, achieving complete bioavailability compared to the mere 10% absorption rate of oral formulations. This breakthrough addresses one of oncology's most persistent challenges: delivering therapeutic drug concentrations to tumors while minimizing exposure to healthy tissues.

The particle size of 20 nanometers represents a critical threshold for optimal drug delivery performance. Conventional chemotherapy and oral targeted therapies often fail to reach tumors at effective concentrations, leading to suboptimal treatment outcomes and severe side effects. Oncotelic's technology overcomes these limitations through precise nanoparticle engineering that maximizes tumor targeting and therapeutic efficacy. The Deciparticle(TM) platform demonstrates how nanoscale precision can transform drug delivery mechanisms in cancer treatment.

The strategic partnership with Medicilon supports Oncotelic's rapid Investigational New Drug platform, enabling acceleration of up to 20 IND projects simultaneously. This collaborative approach significantly shortens development timelines, allowing multiple Deciparticle(TM) drug candidates to progress quickly to clinical testing stages. The platform's efficiency represents a new paradigm in drug development, potentially bringing innovative cancer treatments to patients faster than traditional development pathways.

For investors seeking current information about Oncotelic's progress, updates are available through the company's newsroom at https://ibn.fm/OTLC. The beginning of human trials for Sapu003 validates both the scientific approach and the commercial potential of Oncotelic's nanoparticle technology platform. As nanomedicine continues to evolve, the precise control of particle size emerges as a fundamental factor in achieving therapeutic success, potentially transforming treatment outcomes across multiple cancer types and establishing new standards for targeted drug delivery systems.